Table 1.
Clinicopathological parameters of advanced NSCLC patients and correlation with FAP expression (total n = 135)
| Clinicopathological parameter | Stratification | Frequency (proportion) | FAPhigh | FAPlow | p-value |
|---|---|---|---|---|---|
| Age at diagnosis | < 60 | 49 (36.3%) | 27 | 22 | 0.856 |
| ≥ 60 | 86 (63.7%) | 46 | 40 | ||
| Gender | Male | 108 (80.0%) | 59 | 49 | 0.796 |
| Female | 27 (20.0%) | 14 | 13 | ||
| Smoking history | Yes | 78 (57.8%) | 46 | 32 | 0.181 |
| No | 57 (42.2%) | 27 | 30 | ||
| Histological type | Non-squamous cell carcinoma | 78 (57.8%) | 47 | 31 | 0.092 |
| Squamous cell carcinoma | 57 (42.2%) | 26 | 31 | ||
| TNM Stage | IIIB | 35 (25.9%) | 14 | 21 | 0.052 |
| IV | 100 (74.1%) | 59 | 41 | ||
| LNM | Yes | 98 (72.6%) | 53 | 45 | 0.998 |
| No | 37 (27.4%) | 20 | 17 | ||
| Distant metastasis | Multiple | 51 (37.8%) | 39 | 12 | < 0.001 |
| Solitary | 43 (31.9%) | 16 | 27 | ||
| None | 41 (30.3%) | 18 | 23 | ||
| ECOG PS | ≤ 1 | 118 (87.4%) | 64 | 54 | 0.920 |
| 2 | 17 (12.6%) | 9 | 8 | ||
| Type of immunotherapy | Anti-PD-1 monotherapy | 60 (44.4%) | 36 | 24 | 0.217 |
| Anti-PD-1 + chemotherapy | 75 (55.6%) | 37 | 38 | ||
| Line of systematic treatment | First line | 65 (48.1%) | 37 | 28 | 0.804 |
| Second line | 48 (35.6%) | 25 | 23 | ||
| Third line or later | 22 (16.3%) | 11 | 11 | ||
| Stroma fraction | ≤ 50% | 72 (53.3%) | 41 | 31 | 0.474 |
| > 50% | 63 (46.7%) | 32 | 31 | ||
| CD3 | High | 53 (39.3%) | 26 | 27 | 0.347 |
| Low | 82 (60.7%) | 47 | 35 | ||
| CD8 | High | 50 (37.0%) | 23 | 27 | 0.149 |
| Low | 85 (63.0%) | 50 | 35 | ||
| PD-L1 (TPS) status | Positive | 61 (45.2%) | 32 | 29 | 0.654 |
| Negative | 12 (8.9%) | 8 | 4 | ||
| NA | 62 (45.9%) | 33 | 29 | ||
| PD-L1 (IC) status | Positive | 38 (28.2%) | 26 | 12 | 0.051 |
| Negative | 35 (25.9%) | 14 | 21 | ||
| NA | 62 (45.9%) | 33 | 29 |
LNM lymph node metastasis
ECOG PS Eastern Cooperative Oncology Group Performance Status
PD-1 programmed cell death-1
PD-L1 programmed cell death ligand-1
NA not available